knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 18:16:03 - browse：27

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Tocagen's brain cancer gene therapy trial continues. Investors worry

leisure time

WSS

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Texas Department of Public Safety speaks out on migrant abuse allegations

23andMe had bad news about my health. I wish a person had delivered it

7 more heat

At least 13 dead in Texas as scorching temps continue

Jerome Adams on the need for new antivirals for Covid

hotspot

knowledge

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

What does generative AI mean for health care? We asked experts

Anesthesiologist group: stop taking Ozempic before surgery

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medical leaders decry Supreme Court decision on affirmative action

Drug repurposing or repositioning? The language matters

FDA approval of Sarepta Duchenne genetic therapy gives me hope

As demand for Covid shots wanes, Moderna seeks its next success

State Dept. review finds Biden bears some blame for Afghanistan failures

knowledge

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Apple is now the first public company to be valued at $3 trillion

Novavax promises a turnaround & Lilly roils the obesity market

Winning ticket for $1 billion Powerball jackpot sold in California

Awakening the world to the whoosh: A patient's crusade

State Dept. review finds Biden bears some blame for Afghanistan failures

leisure time

knowledge

focus

leisure time